Insulins today and beyond

被引：307

作者：

Owens, DR

Zinman, B

Bolli, GB

机构：

[1] Llandough Hosp, Diabet Res Unit, Penarth CF64 2XX, S Glam, Wales

[2] Univ Toronto, Mt Sinai Hosp, Toronto, ON, Canada

[3] Univ Perugia, Di M 1, I-06100 Perugia, Italy

来源：

LANCET | 2001年 / 358卷 / 9283期

关键词：

D O I：

10.1016/S0140-6736(01)05842-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The advent of insulin almost 80 years ago revolutionised treatment of diabetes and must be one of the most outstanding achievements of twentieth century medicine. Since then, there has been an ever-increasing awareness and acceptance of the need to achieve and sustain near-normoglycaemia to delay onset and retard progression of diabetic angiopathy. Physiological insulin replacement is therefore central to management of patients with diabetes who are unable to take insulin. Insulin formulations, treatment strategies, and methods, and routes of delivery have changed much, with more and more options for monitoring the effect on blood glucose concentrations. Patients with type 1 and type 2 diabetes need insulin much more aggressively than previously. Parallel developments in glucose-sensing technologies are welcomed as an integral part of safe and optimum implementation of insulin replacement therapy.

引用

页码：739 / 746

页数：8

共 90 条

[1] Optimal provision of daytime NPH insulin in patients using the insulin analog lispro [J].

Ahmed, ABE ;

Home, PD .

DIABETES CARE, 1998, 21 (10) :1707-1713

[2] Optimization of evening insulin dose in patients using the short-acting insulin analog lispro [J].

Ahmed, ABE ;

Mallias, J ;

Home, PD .

DIABETES CARE, 1998, 21 (07) :1162-1166

[3] Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment [J].

Anderson, JH ;

Brunelle, RL ;

Koivisto, VA ;

Pfutzner, A ;

Trautmann, ME ;

Vignati, L ;

DiMarchi, R ;

Bowen, KM ;

Cameron, DP ;

Nankervis, AJ ;

Roberts, AP ;

Zimmet, P ;

Borkenstein, MH ;

Schernthaner, G ;

Waldhausl, WK ;

DeLeeuw, IH ;

Fery, F ;

Scheen, A ;

Somers, G ;

Fettes, IM ;

Tildesley, HD ;

Toth, EL ;

Viikari, J ;

Altman, JJ ;

Bougneres, PF ;

Drouin, P ;

Fossati, P ;

Guillausseau, PJ ;

Marechaud, E ;

Riou, JP ;

Selam, JL ;

Vialettes, PB ;

Beyer, J ;

Federlin, K ;

Fussganger, RD ;

Gries, FA ;

Jastram, HU ;

Koop, I ;

Landgraf, R ;

Rosak, C ;

Schatz, H ;

SchulzeSchleppinghoff, B ;

Seif, FJ ;

Stoeckmann, F ;

Karasik, A ;

Weitzman, S ;

Andreani, D ;

Bompiani, G ;

Crepaldi, G ;

Giorgino, R .

DIABETES, 1997, 46 (02) :265-270

[4]

[Anonymous], 1986, Human Insulin: Clinical Pharmacological Studies in Normal Man, DOI 10.1007/978-94-009-4161-8

[5] Growth promoting and metabolic activity of the human insulin analogue [Gly(A21),Arg(B31),Arg(B32)]insulin (HOE 901) in muscle cells [J].

Bahr, M ;

Kolter, T ;

Seipke, G ;

Eckel, J .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 320 (2-3) :259-265

[6] Insulin analogues [J].

Barnett, AH ;

Owens, DR .

LANCET, 1997, 349 (9044) :47-51

[7] The long acting human insulin analog HOE 901:: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin [J].

Berti, L ;

Kellerer, M ;

Bossenmaier, B ;

Seffer, E ;

Seipke, G ;

Häring, HU .

HORMONE AND METABOLIC RESEARCH, 1998, 30 (03) :123-129

[8]

BEULKESAM J, 1994, J AM COLL TOXICOL, V13, P247

[9] INSULIN PHARMACOKINETICS [J].

BINDER, C ;

LAURITZEN, T ;

FABER, O ;

PRAMMING, S .

DIABETES CARE, 1984, 7 (02) :188-199

[10] Insulin analogues and their potential in the management of diabetes mellitus [J].

Bolli, GB ;

Di Marchi, RD ;

Park, GD ;

Pramming, S ;

Koivisto, VA .

DIABETOLOGIA, 1999, 42 (10) :1151-1167

← 1 2 3 4 5 6 7 8 9 →